Please assess the completion status of the following clinical trial:

Trial Title: R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years~* Patients affected by CLL / SLL~* Presence of active disease defined as the presence of one of the following:~Disease related symptoms (weight loss \>10% in the last 6 months, fever \>38° C for 2 weeks without evidence of infection, or marked asthenia, or profuse sweating without evidence of infection) Massive nodes (at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy Massive (at least 6 cm below left costal margin) or progressive or symptomatic splenomegaly Progressive lymphocytosis (increased \>50% in 2 months) or lymphocyte doubling time \< 6 months Evidence of progressive bone marrow insufficiency seen as evidence of or worsening of anemia and or thrombocytopenia Autoimmune anemia and or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy~Exclusion Criteria:~* Age \< 18 years~* Patients with cardiac, pulmonary, neurological, psychiatric or serious metabolic conditions not related to CLL / SLL~* Altered hepatic function (bilirubin, GOT, GPT, or gammaGT \> 2 times upper limit of normal) not attributable to CLL / SLL~* Altered renal function (creatinine \> 1,5 times upper limit of normal)~* Patients with serious active infections~* Pregnancy and/ or breastfeeding~* Patients with positive serology for HBSAG or HBCAB without evaluation by a hepatologist~* Patients with positive serology for HIV~* Life expectancy of less than 12 months~* Not taking any other experimental drugs~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cladribine (2CdA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab cladribine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).